Multiparameter flow cytometric analysis of Mouse CD3ε expression on C57BL/6 mouse splenocytes. C57BL/6 mouse splenocytes were stained with Alexa Fluor® 647 Rat Anti-Mouse CD19 antibody and either Pacific Blue Mouse IgG1, κ Isotype Control (Left panel) or SDT Pacific Blue Mouse Anti-Mouse CD3ε Antibody (Right panel) at 0.25 μg/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
Product Details
Product Details
Product Specification
Host | Mouse |
Antigen | Mouse CD3ε |
Synonyms | T-cell surface glycoprotein CD3 epsilon chain; T-cell surface antigen T3/Leu-4 epsilon chain |
Location | Cell membrane |
Accession | P22646 |
Clone Number | S-R384 |
Antibody Type | Mouse mAb |
Isotype | IgG1,k |
Application | FCM |
Reactivity | Ms |
Positive Sample | C57BL/6 mouse splenocytes |
Purification | Protein G |
Concentration | 0.05mg/ml |
Conjugation | Pacific Blue |
Physical Appearance | Liquid |
Storage Buffer | PBS, 25% Glycerol, 1% BSA, 0.3% Proclin 300 |
Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied. |
Dilution
application | dilution | species |
FCM | 5 μl per million cells in 100μl volume | Ms |
Background
CD3 (cluster of differentiation 3) is a protein complex and T cell co-receptor that is involved in activating both the cytotoxic T cell (CD8+ naive T cells) and T helper cells (CD4+ naive T cells). It is composed of four distinct chains. In mammals, the complex contains a CD3γ chain, a CD3δ chain, and two CD3ε chains. These chains associate with the T-cell receptor (TCR) and the CD3-zeta (ζ-chain) to generate an activation signal in T lymphocytes. The TCR, CD3-zeta, and the other CD3 molecules together constitute the TCR complex. The CD3–T cell receptor (TCR) complex plays a central role in the T-cell-mediated immunoresponse as it is involved in the recognition of antigens and subsequent signal transduction and activation of immunocompetent T lymphocytes. Because CD3 is required for T cell activation, drugs (often monoclonal antibodies) that target it are being investigated as immunosuppressant therapies (e.g., otelixizumab, teplizumab) for type 1 diabetes and other autoimmune diseases.
Picture
Picture
FC
